Effectiveness of Cabergoline Treatment in Patients with Acromegaly Uncontrolled with SSAs: Experience of a Single Tertiary Center

Abstract

Purpose To evaluate the effectiveness of cabergoline and the parameters affecting cabergoline response as add-on treatment to somatostatin analaogues (SSA) in patients with acromegaly uncontrolled with SSAs.

Material and Method One hundred and twenty-nine acromegalic patients uncontrolled with SSA who had cabergoline added to their treatment were included in this retrospective study. Patients were divided into the SSAs + cabergoline-responsive (group 1) and non-responsive groups (group 2), and biochemical, pathologic, and radiologic parameters were assessed.

Results IGF-1 normalization was achieved in 75 of 129 patients (58%) when cabergoline was added to the SSA treatment. Female patients were significantly higher in group 1 compared to group 2 (p=0.006). Group 1 had significantly smaller pre- and post-cabergoline tumor size (p=0.011, p=0.007 respectively), lower levels of IGF-1 in pre-and post-operative period (p=0.040, p=0.001), and lower levels of IGF-1 in pre- and post-cabergoline treatment (p<0.001). Cavernous invasion on sellar magnetic resonance imaging, dural invasion in pathologic examination were not significantly different between the groups. Sellar invasion in pathologic examination was significantly higher in group 1 (p=0.011). No significant difference was found in proliferation indices between two groups. The presence of fibrous bodies was significantly lower in group 1 (p=0.010).

Conclusion Cabergoline can be added to the treatment of acromegalic patients uncontrolled with SSAs due to its ease of use and low economic cost, especially in patients with acromegaly who have small adenomas and no fibrous bodies.

Key words

Acromegaly - cabergoline - combined therapy - somatostatin analogue

Publikationsverlauf

Eingereicht: 28. April 2020
Eingereicht: 24. September 2020

Angenommen: 29. September 2020

Artikel online veröffentlicht:
23. Oktober 2020

• References

• 1 Chanson P, Salenave S, Kamenicky P. et al. Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 2009; 23: 555-574
• 2 Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009; 119: 3189-3202
• 3 Melmed S, Katznelson L, Treatment of acromegaly. UpToDate. Jul 2019 (Accessed December 15, 2019)
• 4 Webster J, Piscitelli G, Polli A. et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904-909
• 5 Nutt JG, Wooten GF. Diagnosis and initial management of Parkinson’s disease. N Engl J Med 2005; 353: 1021-1027
• 6 Gillam MP, Molitch ME, Lombardi G. et al. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534
• 7 Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: A meta-analysis. J Clin Endocrinol Metab 2011; 96: 1327-1335
• 8 Colao A, Ferone D, Marzullo P. et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997; 82: 518-523
• 9 Jackson SN, Fowler J, Howlett TA. Cabergoline treatment of acromegaly: A preliminary dose finding study. Clin Endocrinol (Oxf) 1997; 46: 745-749
• 10 Cozzi R, Attanasio R, Lodrini S. et al. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004; 61: 209-215
• 11 Gatta B, Hau DH, Catargi B. et al. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf) 2005; 63: 477-478
• 12 Rocheville M, Lange DC, Kumar U. et al. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 2000; 288: 154-157
• 13 Katznelson L, Laws ER, Melmed S. et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
• 14 Gola M, Bonadonna S, Mazziotti G. et al. Resistance to somatostatin analogs in acromegaly: An evolving concept?. J Endocrinol Invest 2006; 29: 86-93
• 15 Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: A literature review. Pituitary 2011; 14: 184-193
• 16 Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: Beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 2009; 90: 82-92
• 17 Vilar L, Azevedo MF, Naves LA. et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 2011; 14: 148-156
• 18 Van der Lely AJ, Harris AG, Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 1992; 37: 181-185
• 19 Kiseljak-Vassiliades K, Carlson NE, Borges MT. et al. Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 2015; 49: 231-241
• 20 Colao A, Amato G, Pedroncelli AM. et al. Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest 2002; 25: 532-538
• 21 Sherlock M, Fernandez-Rodriguez E, Alonso AA. et al. Medical therapy in patients with acromegaly: Predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab 2009; 94: 1255-1263
• 22 Abs R, Verhelst J, Maiter D. et al. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 1998; 83: 374-378
• 23 Bevan JS, Atkin SL, Atkinson AB. et al. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87: 4554-4563
• 24 Colao A, Pivonello R, Auriemma RS. et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: A prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91: 2112-2118
• 25 Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005; 153: 187-193
• 26 Ezzat S, Kontogeorgos G, Redelmeier DA. et al. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995; 133: 686-690
• 27 Osamura RY, Kajiya H, Takei M. et al. Pathology of the human pituitary adenomas. Histochem Cell Biol 2008; 130: 495-507
• 28 Fusco A, Zatelli MC, Bianchi A. et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 2008; 93: 2746-2750
• 29 Amirjmshidi A, Alimohamadi M, Ownagh V. et al. The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study. Asian J Neurosurg 2014; 9: 130-136